Stabilizing Camptothecin Pharmaceutical Compositions

A storage stabilized liposomal irinotecan composition comprising irinotecan sucrose octasulfate (SOS) encapsulated in liposomes comprising cholesterol and one or more phospholipids, said composition having:

• (i) an irinotecan moiety amount equivalent to that provided by 500 g (±10%) irinotecan free anhydrous base per mol phospholipid;
• (ii) an irinotecan/sulfate compound gram-equivalent ratio of from 0.85 to 1.1, calculated for each irinotecan liposome preparation by determining molar amounts of liposomally co-encapsulated irinotecan (I) and sulfate compound(S) per unit of the liposome composition, and using the formula:
• ER=I/(SN), where N=8;
• (iii) a pH after manufacture and before storage between 7.1 and 7.5 at room temperature;
• and
• wherein, after the first 6 months storage of said composition at a storage temperature of from 2-8° C., there is less than 20 mol % lyso-phosphatidylcholine (“lyso-PC”), relative to the total phospholipids.